Viking Therapeutics' obesity drug shows 22% weight loss in study

VKTX•2026-09-22

Study results

Sept. 22 (Reuters) - Viking Therapeutics said on Tuesday its experimental GLP-1 obesity drug helped patients lose 22% of their body weight after 33 weeks of weekly treatment in a maintenance study.

Viking Therapeutics' obesity drug shows 22% weight loss in study

Study results

Related News

China Probes DeepSeek, Moonshot Over Potential Data Leaks To Anthropic

Roche's obesity drug boosts blood sugar control, drives 15.5% weight loss in mid-stage trial

GSK Canada & Pan-Canadian Pharmaceutical Alliance Sign LOI For Blenrep For A Type Of Multiple Myeloma

Peloton Launches Foldable Peloton Tread Flex – Its Most Affordable Treadmill Ever And New AI-Powered Coaching Features For Runners, Walkers And Hikers

Thor Industries up after beating quarterly revenue estimates